How promising are combinatorial drug strategies in combating Candida albicans biofilms?

References

• 1 Progress report 2014 of Transatlantic Task Force on antimicrobial resistance (TATFAR). www.cdc.gov/drugresistance/pdf/tatfar-progress_report_2014.pdf.
  Google Scholar
• 2 Shallcross LJ, Howard SJ, Fowler T, Davies SC. Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370(1670), 20140082 (2015).
  MedlineGoogle Scholar
• 3 Muzny CA, Schwebke JR. Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin. Infect. Dis. 61(4), 601–606 (2015).
  Medline CASGoogle Scholar
• 4 Davies D. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2(2), 114–122 (2003).
  Medline CASGoogle Scholar
• 5 Lafleur MD, Qi Q, Lewis K. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob. Agents Chemother. 54(1), 39–44 (2010).
  Medline CASGoogle Scholar
• 6 Ramage G, Williams C. The clinical importance of fungal biofilms. Adv. Appl. Microbiol. 84, 27–83 (2013).
  Medline CASGoogle Scholar
• 7 Nett JE. The host's reply to Candida biofilm. Pathogens 5(1), pii: E33 (2016).
  MedlineGoogle Scholar
• 8 De Cremer K, Staes I, Delattin N, Cammue BP, Thevissen K, De Brucker K. Combinatorial drug approaches to tackle Candida albicans biofilms. Expert Rev. Anti Infect. Ther. 13(8), 973–984 (2015).
  Medline CASGoogle Scholar
• 9 Delattin N, Cammue BP, Thevissen K. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future Med. Chem. 6(1), 77–90 (2014).
  CASGoogle Scholar
• 10 Azevedo MM, Teixeira-Santos R, Silva AP et al. The effect of antibacterial and non-antibacterial compounds alone or associated with antifugals upon fungi. Front. Microbiol. 6, 669, eCollection (2015).
  MedlineGoogle Scholar
• 11 Candoni A, Caira M, Cesaro S et al. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses 57(6), 342–350 (2014).
  Medline CASGoogle Scholar
• 12 Delattin N, De Brucker K, De Cremer K, Cammue BPA, Thevissen K. Antimicrobial peptides as a strategy to combat fungal biofilms. Curr. Top. Med. Chem. (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 13 Vriens K, Cools TL, Harvey PJ et al. Synergistic activity of the plant defensin HsAFP1 and caspofungin against Candida albicans biofilms and planktonic cultures. PLoS ONE 10(8), e0132701 (2015).
  MedlineGoogle Scholar
• 14 Chang W, Li Y, Zhang L, Cheng A, Liu Y, Lou H. Retigeric acid B enhances the efficacy of azoles combating the virulence and biofilm formation of Candida albicans. Biol. Pharm. Bull. 35(10), 1794–1801 (2012).
  Medline CASGoogle Scholar
• 15 Lafleur MD, Sun L, Lister I et al. Potentiation of azole antifungals by 2-adamantanamine. Antimicrob. Agents Chemother. 57(8), 3585–3592 (2013).
  Medline CASGoogle Scholar
• 16 Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob. Agents Chemother. 52(3), 1127–1132 (2008).
  Medline CASGoogle Scholar
• 17 Bink A, Kucharíková S, Neirinck B et al. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms. J. Infect. Dis. 206(11), 1790–1797 (2012).
  Medline CASGoogle Scholar